Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Redirecting T-Cells Against AML in a Multidimensional Targeting Space Using T-Cell Engaging Antibody Circuits (TEAC)

Eleanor Minogue, BSc, David Millar, PhD, Yan Chuan, PhD, Songfa Zhang, MD PhD, Korneel Grauwet, PhD, Mei Guo, Adam Langenbucher, Cyril H Benes, James Heather, PhD, Jeremy Minshull, PhD, Michael S. Lawrence, PhD, Rupa Narayan, David M. Langenau, PhD, Timothy A. Graubert, MD, Mark Cobbold

Blood (2019) 134 (Supplement_1): 2653.

https://doi.org/10.1182/blood-2019-127634

Published: 2019

Journal Articles

Preclinical Rationale for the Use of Regorafenib in Myeloid Malignancies

Gabriela S. Hobbs, MD, Andrew M. Brunner, MD, Timothy A. Graubert, MD, Cyril H Benes, Gabriel Daniel Duda, DMD, PhD, Yi-Bin Chen, MD

Blood (2017) 130 (Supplement 1): 2643.

https://doi.org/10.1182/blood.V130.Suppl_1.2643.2643

Published: 2017

Journal Articles

Single Agent and Synergistic Combinatorial Efficacy of First-in-Class Small Molecule Imipridone ONC201 in Hematological Malignancies In Vitro and In Vivo through Apoptosis Via the Integrated Stress Response Pathway

Varun Vijay Prabhu, BPharm, MS, PhD, Mala Kiran Talekar, MD, Amriti R Lulla, MS, C. Leah B Kline, Lanlan Zhou, Junior Hall, A. Pieter J Van den Heuvel, David T Dicker, Stephan A Grupp, MD PhD, Mathew Garnett, Ultan McDermott, Cyril H Benes, Jeffrey J Pu, David F Claxton, MD, Wolfgang Oster, MD, Joshua E. Allen, PhD, Wafik S. El-Deiry

Blood (2017) 130 (Supplement 1): 3842.

https://doi.org/10.1182/blood.V130.Suppl_1.3842.3842

Published: 2017

Journal Articles

The Novel Imipridone ONC212 Induces Pronounced Anti-Leukemia Effects in Vitro and In Vivo and Is Highly Synergistic with the BCL-2 Inhibitor ABT-199

Takenobu Nii, PhD, Jo Ishizawa, MD PhD, Varun Vijay Prabhu, BPharm, MS, PhD, Vivian Ruvolo, PhD, Neel Madhukar, Ran Zhao, Hong Mu, MD PhD, Lauren Heese, Kensuke Kojima, MD PhD, Mathew Garnett, Ultan McDermott, Cyril H Benes, Neil Charter, Sean Deacon, Olivier Elemento, PhD, Joshua E. Allen, PhD, Wolfgang Oster, MD, Martin Stogniew, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 2616.

https://doi.org/10.1182/blood.V130.Suppl_1.2616.2616

Published: 2017

Journal Articles

Single Agent and Combinatorial Efficacy of First-in-Class Small Molecule ONC201 in Acute Leukemia and Multiple Myeloma

Varun V Prabhu, PhD, Amriti Lulla, Christina L Kline, PhD, Peter J Van den Heuvel, PhD, Mala K. Talekar, MD, Jessica M Wagner, Rohinton S Tarapore, PhD, David T Dicker, Mathew J Garnett, PhD, Ultan McDermott, MD PhD, Cyril H Benes, PhD, Jeffrey J. Pu, MD PhD, David F. Claxton, MD, Wolfgang Oster, MD PhD, Joshua E Allen, PhD, Wafik S. El-Deiry, MD PhD

Blood (2016) 128 (22): 2759.

https://doi.org/10.1182/blood.V128.22.2759.2759

Published: 2016

Journal Articles

Potent Anti-Leukemic Effects of Small Molecule ONC212, a Member of the Imipridone Class of Anti-Cancer Compounds

Varun V Prabhu, PhD, Rohinton S Tarapore, PhD, Mathew J Garnett, PhD, Ultan McDermott, MD PhD, Cyril H Benes, PhD, Jessica M Wagner, Wafik S. El-Deiry, MD PhD, Martin Stogniew, PhD, Wolfgang Oster, MD PhD, Joshua E Allen, PhD

Blood (2016) 128 (22): 5133.

https://doi.org/10.1182/blood.V128.22.5133.5133

Published: 2016

NARROW

Redirecting T-Cells Against AML in a Multidimensional Targeting Space Using T-Cell Engaging Antibody Circuits (TEAC)

Preclinical Rationale for the Use of Regorafenib in Myeloid Malignancies

Single Agent and Synergistic Combinatorial Efficacy of First-in-Class Small Molecule Imipridone ONC201 in Hematological Malignancies In Vitro and In Vivo through Apoptosis Via the Integrated Stress Response Pathway

The Novel Imipridone ONC212 Induces Pronounced Anti-Leukemia Effects in Vitro and In Vivo and Is Highly Synergistic with the BCL-2 Inhibitor ABT-199

Single Agent and Combinatorial Efficacy of First-in-Class Small Molecule ONC201 in Acute Leukemia and Multiple Myeloma

Potent Anti-Leukemic Effects of Small Molecule ONC212, a Member of the Imipridone Class of Anti-Cancer Compounds

Email alerts

ASH Publications

American Society of Hematology

Redirecting T-Cells Against AML in a Multidimensional Targeting Space Using T-Cell Engaging Antibody Circuits (TEAC)

Preclinical Rationale for the Use of Regorafenib in Myeloid Malignancies

Single Agent and Synergistic Combinatorial Efficacy of First-in-Class Small Molecule Imipridone ONC201 in Hematological Malignancies In Vitro and In Vivo through Apoptosis Via the Integrated Stress Response Pathway

The Novel Imipridone ONC212 Induces Pronounced Anti-Leukemia Effects in Vitro and In Vivo and Is Highly Synergistic with the BCL-2 Inhibitor ABT-199

Single Agent and Combinatorial Efficacy of First-in-Class Small Molecule ONC201 in Acute Leukemia and Multiple Myeloma

Potent Anti-Leukemic Effects of Small Molecule ONC212, a Member of the Imipridone Class of Anti-Cancer Compounds

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only